MA43549A - Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants - Google Patents

Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants

Info

Publication number: MA43549A
Authority: MA; Morocco
Prior art keywords: alpha; salt; crystalline form; amino esters; polymorphic crystalline
Prior art date: 2016-01-04

Application number

MA043549A

Other languages

English (en)

Inventor

Jean-Pierre Gotteland

Catherine Jorand-Lebrun

Ernest Loumaye

Page Patrick Naxos

Oliver Pohl

Vincent Pomel

Anna Quattropani

Matthias Schwarz

Original Assignee

ObsEva SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-04

Filing date

2017-01-04

Publication date

2021-05-26

2016-01-04 Priority claimed from US14/987,586 external-priority patent/US9447055B1/en

2017-01-04 Application filed by ObsEva SA filed Critical ObsEva SA

2021-05-26 Publication of MA43549A publication Critical patent/MA43549A/fr

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Thiazole And Isothizaole Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cephalosporin Compounds (AREA)
Rheumatology (AREA)
Pyrrole Compounds (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)

MA043549A 2016-01-04 2017-01-04 Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants MA43549A (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201662274674P	2016-01-04	2016-01-04
US14/987,586 US9447055B1 (en)	2016-01-04	2016-01-04	α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US201662395664P	2016-09-16	2016-09-16
US201662407918P	2016-10-13	2016-10-13

Publications (1)

Publication Number	Publication Date
MA43549A true MA43549A (fr)	2021-05-26

Family

ID=57799697

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA043580A MA43580A (fr)	2016-01-04	2017-01-04	L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants
MA043549A MA43549A (fr)	2016-01-04	2017-01-04	Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA043580A MA43580A (fr)	2016-01-04	2017-01-04	L-valinate d'un dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants

Country Status (25)

Country	Link
EP (4)	EP3400217B1 (fr)
JP (6)	JP6933322B2 (fr)
KR (3)	KR20250107965A (fr)
CN (1)	CN108779087A (fr)
AU (5)	AU2017205670B2 (fr)
CA (2)	CA3009576A1 (fr)
CY (2)	CY1125231T1 (fr)
DK (2)	DK3397622T3 (fr)
EA (1)	EA036990B1 (fr)
ES (2)	ES2916835T3 (fr)
HR (2)	HRP20220674T1 (fr)
HU (2)	HUE058872T2 (fr)
IL (5)	IL318222A (fr)
LT (2)	LT3400217T (fr)
MA (2)	MA43580A (fr)
MX (3)	MX389261B (fr)
PL (2)	PL3400217T3 (fr)
PT (2)	PT3400217T (fr)
RS (2)	RS63285B1 (fr)
SG (4)	SG11201804594YA (fr)
SI (2)	SI3400217T1 (fr)
SM (2)	SMT202200248T1 (fr)
UA (2)	UA125377C2 (fr)
WO (2)	WO2017118639A1 (fr)
ZA (1)	ZA201903769B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT3400217T (lt) *	2016-01-04	2022-06-27	Merck Serono S.A.	Hidroksipropiltiazolidino karboksamido l-valinato darinys, jo druska ir jo kristalinė forma
RU2711615C1 (ru) *	2019-09-12	2020-01-17	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта"	Способ лечения эндометриоза на основании экспериментальной модели у крыс
CA3152099A1 (fr) *	2019-09-23	2021-04-01	Liang Liang	Procedes de traitement de prolongation de la gestation et des complications des menstruations ou de la gestation
US12426782B2 (en)	2020-11-06	2025-09-30	The Board Of Trustees Of The Leland Stanford Junior University	Systems and temporal alignment methods for evaluation of gestational age and time to delivery
WO2022125876A1 (fr) *	2020-12-11	2022-06-16	Olsen Elise A	Compositions et procédés destinés à inhiber la croissance pileuse

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3835175A (en)	1971-03-15	1974-09-10	Research Corp	9-fluorenylmethanol haloformates, carbonates and thiocarbonates
US3839396A (en)	1971-07-15	1974-10-01	Shionogi & Co	9-lower alkyl-9-fluorenyl carbonates
US4108846A (en)	1977-02-01	1978-08-22	Hoffmann-La Roche Inc.	Solid phase synthesis with base N alpha-protecting group cleavage
SE430885B (sv)	1980-03-24	1983-12-19	Ferring Ab	Oxytocin-derivat
US4581167A (en)	1982-01-19	1986-04-08	Research Corporation	Peptide synthesis and amino acid blocking agents
US4508657A (en)	1982-01-19	1985-04-02	Research Corporation	Peptide synthesis and amino acid blocking agents
US4504469A (en)	1982-12-21	1985-03-12	Ferring Ab	Vasotocin derivatives
US4460501A (en)	1983-08-30	1984-07-17	Research Corporation	Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides
US5370135A (en) *	1993-10-13	1994-12-06	Biex, Inc.	Use of estriol measurement to monitor tocolytic therapy
DE4434488A1 (de) *	1994-09-14	1996-03-21	Schering Ag	Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
SE9604341D0 (sv)	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue
IN188411B (fr) *	1997-03-27	2002-09-21	Yuhan Corp
AU2001261161A1 (en) *	2000-05-30	2001-12-11	Ortho-Mcneil Pharmaceutical, Inc.	Dihydropyridine compounds for inhibition of calcium-influx
GB0130677D0 (en)	2001-12-21	2002-02-06	Glaxo Group Ltd	Medicaments and novel compounds
AU2003211011A1 (en)	2002-02-27	2003-09-09	Ferring Bv	Intermediates and methods for making heptapeptide oxytocin analogues
RS81604A (sr)	2002-03-28	2006-12-15	Applied Research Systems Ars Holding N.V.	Derivati tijazolidin karboksamida kao modulatori receptora prostaglandina f
GB0208785D0 (en) *	2002-04-17	2002-05-29	Medical Res Council	Treatment methtods
US7521530B2 (en) *	2002-06-11	2009-04-21	Universite De Montreal	Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
UA78058C2 (en)	2002-07-05	2007-02-15	Applied Research Systems	Pyrrolidine derivative as oxitocin antagonists
MXPA05006230A (es) *	2002-12-12	2005-09-20	Idenix Cayman Ltd	Proceso para la produccion de nucleosidos ramificados-2'.
GB0314738D0 (en)	2003-06-24	2003-07-30	Glaxo Group Ltd	Novel compounds
GB0414093D0 (en)	2004-06-23	2004-07-28	Glaxo Group Ltd	Novel compounds
EP2493874A1 (fr)	2009-10-30	2012-09-05	Glaxo Group Limited	Nouvelles formes cristallines de (3r,6r) -3- (2, 3 -dihydro- 1h- inden- 2 -yl) - 1 - [ (1r) - 1 - (2, 6 - diméthyl - 3 - pyridinyl) - 2 - (4 -morpholinyl) -2-oxoéthyl]-6- [(1s) - 1 -méthylpropyl]-2,5- pipérazinedione
EP2845850A1 (fr)	2013-09-10	2015-03-11	ObsEva S.A.	Dérivés de pyrrolidine comme antagonistes des récepteurs V1a de vasopressine/oxytocine
EP2886107A1 (fr)	2013-12-17	2015-06-24	ObsEva S.A.	Formules orales de dérivés de pyrrolydine
AU2014397706A1 (en) *	2014-06-16	2016-12-22	Glaxosmithkline Intellectual Property Development Limited	Retosiban for the treatment of pre-term labour
CN114105851A (zh)	2014-07-02	2022-03-01	奥布赛瓦股份公司	治疗ot-r活性相关的病症的方法中可用的晶体
ES2716862T3 (es)	2014-12-22	2019-06-17	Ferring Bv	Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
US9447055B1 (en) *	2016-01-04	2016-09-20	Merck Serono S.A.	α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
LT3400217T (lt) *	2016-01-04	2022-06-27	Merck Serono S.A.	Hidroksipropiltiazolidino karboksamido l-valinato darinys, jo druska ir jo kristalinė forma

2017
- 2017-01-04 LT LTEPPCT/EP2017/050101T patent/LT3400217T/lt unknown
- 2017-01-04 CA CA3009576A patent/CA3009576A1/fr active Pending
- 2017-01-04 RS RS20220547A patent/RS63285B1/sr unknown
- 2017-01-04 SI SI201731161T patent/SI3400217T1/sl unknown
- 2017-01-04 KR KR1020257022032A patent/KR20250107965A/ko active Pending
- 2017-01-04 KR KR1020187018312A patent/KR20180100120A/ko not_active Ceased
- 2017-01-04 SG SG11201804594YA patent/SG11201804594YA/en unknown
- 2017-01-04 EP EP17700392.8A patent/EP3400217B1/fr active Active
- 2017-01-04 KR KR1020187018929A patent/KR102795275B1/ko active Active
- 2017-01-04 SG SG10202009769WA patent/SG10202009769WA/en unknown
- 2017-01-04 MA MA043580A patent/MA43580A/fr unknown
- 2017-01-04 JP JP2018529634A patent/JP6933322B2/ja active Active
- 2017-01-04 CA CA3009573A patent/CA3009573A1/fr active Pending
- 2017-01-04 HU HUE17700391A patent/HUE058872T2/hu unknown
- 2017-01-04 SI SI201731162T patent/SI3397622T1/sl unknown
- 2017-01-04 HU HUE17700392A patent/HUE058871T2/hu unknown
- 2017-01-04 HR HRP20220674TT patent/HRP20220674T1/hr unknown
- 2017-01-04 PL PL17700392T patent/PL3400217T3/pl unknown
- 2017-01-04 ES ES17700392T patent/ES2916835T3/es active Active
- 2017-01-04 PL PL17700391T patent/PL3397622T3/pl unknown
- 2017-01-04 AU AU2017205670A patent/AU2017205670B2/en active Active
- 2017-01-04 UA UAA201806074A patent/UA125377C2/uk unknown
- 2017-01-04 HR HRP20220673TT patent/HRP20220673T1/hr unknown
- 2017-01-04 IL IL318222A patent/IL318222A/en unknown
- 2017-01-04 MX MX2018008157A patent/MX389261B/es unknown
- 2017-01-04 CN CN201780015011.9A patent/CN108779087A/zh active Pending
- 2017-01-04 PT PT177003928T patent/PT3400217T/pt unknown
- 2017-01-04 ES ES17700391T patent/ES2915948T3/es active Active
- 2017-01-04 SM SM20220248T patent/SMT202200248T1/it unknown
- 2017-01-04 SG SG10202009723PA patent/SG10202009723PA/en unknown
- 2017-01-04 LT LTEPPCT/EP2017/050099T patent/LT3397622T/lt unknown
- 2017-01-04 MA MA043549A patent/MA43549A/fr unknown
- 2017-01-04 WO PCT/EP2017/050099 patent/WO2017118639A1/fr not_active Ceased
- 2017-01-04 AU AU2017205254A patent/AU2017205254B2/en active Active
- 2017-01-04 UA UAA201806830A patent/UA125118C2/uk unknown
- 2017-01-04 EP EP17700391.0A patent/EP3397622B1/fr active Active
- 2017-01-04 WO PCT/EP2017/050101 patent/WO2017118641A1/fr not_active Ceased
- 2017-01-04 EP EP22153566.9A patent/EP4144351A1/fr active Pending
- 2017-01-04 JP JP2018529284A patent/JP7169573B2/ja active Active
- 2017-01-04 IL IL284912A patent/IL284912B/en unknown
- 2017-01-04 MX MX2018008304A patent/MX379544B/es unknown
- 2017-01-04 SG SG11201804789QA patent/SG11201804789QA/en unknown
- 2017-01-04 DK DK17700391.0T patent/DK3397622T3/da active
- 2017-01-04 EP EP22152238.6A patent/EP4140988A1/fr active Pending
- 2017-01-04 DK DK17700392.8T patent/DK3400217T3/da active
- 2017-01-04 EA EA201891095A patent/EA036990B1/ru unknown
- 2017-01-04 RS RS20220548A patent/RS63286B1/sr unknown
- 2017-01-04 PT PT177003910T patent/PT3397622T/pt unknown
- 2017-01-04 SM SM20220249T patent/SMT202200249T1/it unknown
2018
- 2018-05-31 IL IL259742A patent/IL259742B/en unknown
- 2018-06-26 IL IL260286A patent/IL260286B/en unknown
- 2018-06-29 MX MX2022000154A patent/MX2022000154A/es unknown
2019
- 2019-05-24 ZA ZA2019/03769A patent/ZA201903769B/en unknown
2021
- 2021-08-05 JP JP2021129297A patent/JP7432284B2/ja active Active
- 2021-08-16 AU AU2021218009A patent/AU2021218009B2/en active Active
- 2021-12-22 IL IL289256A patent/IL289256A/en unknown
2022
- 2022-06-01 CY CY20221100384T patent/CY1125231T1/el unknown
- 2022-06-01 CY CY20221100383T patent/CY1125223T1/el unknown
- 2022-10-18 JP JP2022166814A patent/JP7377588B2/ja active Active
2023
- 2023-09-21 AU AU2023233151A patent/AU2023233151A1/en not_active Abandoned
- 2023-10-25 JP JP2023183345A patent/JP2024012376A/ja active Pending
2025
- 2025-09-04 JP JP2025147215A patent/JP2026000959A/ja active Pending
- 2025-10-22 AU AU2025256134A patent/AU2025256134A1/en active Pending

Also Published As

Publication number	Publication date
MX389261B (es)	2025-03-20
JP7432284B2 (ja)	2024-02-16
KR102795275B1 (ko)	2025-04-11
IL260286B (en)	2022-02-01
AU2017205670A1 (en)	2018-08-16
PL3397622T3 (pl)	2022-07-04
CA3009576A1 (fr)	2017-07-13
EA036990B1 (ru)	2021-01-25
JP2024012376A (ja)	2024-01-30
AU2023233151A1 (en)	2023-10-12
IL259742A (en)	2018-07-31
SI3397622T1 (sl)	2022-07-29
MX2022000154A (es)	2022-02-21
AU2017205254A1 (en)	2018-08-16
IL260286A (en)	2018-07-31
SI3400217T1 (sl)	2022-07-29
PL3400217T3 (pl)	2022-07-04
SG11201804594YA (en)	2018-06-28
SG10202009723PA (en)	2020-11-27
SG11201804789QA (en)	2018-07-30
SG10202009769WA (en)	2020-11-27
EP3397622A1 (fr)	2018-11-07
MX2018008304A (es)	2019-01-24
AU2025256134A1 (en)	2025-11-13
JP7169573B2 (ja)	2022-11-11
JP6933322B2 (ja)	2021-09-08
CN108779087A (zh)	2018-11-09
EP4144351A1 (fr)	2023-03-08
LT3400217T (lt)	2022-06-27
ZA201903769B (en)	2023-03-29
PT3400217T (pt)	2022-06-15
CA3009573A1 (fr)	2017-07-13
MX2018008157A (es)	2018-09-03
AU2021218009A1 (en)	2021-09-09
UA125377C2 (uk)	2022-03-02
EP4140988A1 (fr)	2023-03-01
LT3397622T (lt)	2022-06-27
AU2021218009B2 (en)	2023-06-22
JP2021178858A (ja)	2021-11-18
HRP20220673T1 (hr)	2022-07-08
JP2019500351A (ja)	2019-01-10
WO2017118641A1 (fr)	2017-07-13
DK3397622T3 (en)	2022-06-07
AU2017205254B2 (en)	2021-05-20
JP7377588B2 (ja)	2023-11-10
EP3397622B1 (fr)	2022-03-09
MA43580A (fr)	2021-05-26
HRP20220674T1 (hr)	2022-07-22
DK3400217T3 (da)	2022-06-07
MX379544B (es)	2025-03-11
EP3400217A1 (fr)	2018-11-14
KR20180099708A (ko)	2018-09-05
IL284912A (en)	2021-08-31
WO2017118639A1 (fr)	2017-07-13
CY1125231T1 (el)	2025-03-28
IL289256A (en)	2022-02-01
RS63285B1 (sr)	2022-06-30
AU2017205670B2 (en)	2021-05-20
AU2021218003A1 (en)	2021-09-02
IL284912B (en)	2022-07-01
KR20180100120A (ko)	2018-09-07
HUE058872T2 (hu)	2022-09-28
JP2019501897A (ja)	2019-01-24
ES2915948T3 (es)	2022-06-27
IL318222A (en)	2025-03-01
ES2916835T3 (es)	2022-07-06
HUE058871T2 (hu)	2022-09-28
PT3397622T (pt)	2022-06-15
SMT202200249T1 (it)	2022-07-21
UA125118C2 (uk)	2022-01-12
KR20250107965A (ko)	2025-07-14
SMT202200248T1 (it)	2022-07-21
EP3400217B1 (fr)	2022-03-09
JP2026000959A (ja)	2026-01-06
CY1125223T1 (el)	2025-03-28
RS63286B1 (sr)	2022-06-30
IL259742B (en)	2021-08-31
EA201891095A1 (ru)	2019-01-31
JP2023002668A (ja)	2023-01-10

Publication	Publication Date	Title
EP3438099A4 (fr)	2019-02-06	Sel d'acide pamoïque de vortioxétine et sa forme cristalline
PL3638666T3 (pl)	2022-01-03	Chwastobójczo skuteczne 3-fenyloizoksazolino-5-karboksyamidy amidów kwasu tetrahydro- i dihydrofuranokarboksylowego
EP3365344A4 (fr)	2019-05-22	Sel d'un inhibiteur d'egfr, forme cristalline correspondante et utilisations correspondantes
MA53226A (fr)	2021-11-24	Sel et formes cristallines d'omecamtiv mecarbil
EP3453703A4 (fr)	2019-03-20	Forme cristalline e d'un sel de tafamidis méthylglucamine, son procédé de préparation et son application
MA46866A (fr)	2021-06-02	Une forme cristalline d'un inhibiteur de magl
LT3191461T (lt)	2021-12-10	6-karboksi-2-(3,5-dichlorfenil)-benzoksazolo kristalinės kietos formos
MA46972A (fr)	2019-10-09	Forme polymorphe de sépiaptérine
MA43549A (fr)	2021-05-26	Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants
EP3337485A4 (fr)	2019-01-09	Formes cristallines d'ibrutinib
EP3699245A4 (fr)	2021-07-14	Assortiment d'encres
LT3519394T (lt)	2020-09-25	Kalkobutrolio modifikacijos kristalinės formos gavimo būdas
EP3668876A4 (fr)	2021-04-28	Forme polymorphe de tg02
SG11201705924RA (en)	2017-08-30	CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb>
MA48944A (fr)	2020-04-08	Forme cristalline de n-butyldéoxygalactonojirimycine
EP3521276A4 (fr)	2019-08-07	Forme cristalline, forme de sel, et procédé de préparation d'inhibiteur de tyrosine kinase
EP3470410A4 (fr)	2019-12-04	Forme cristalline du composé supprimant l'activité de la protéine kinase et application associée
GB201708390D0 (en)	2017-07-12	Novel alpha-amino amide derivatives
EP3305768A4 (fr)	2019-02-13	Sel de sodium d'inhibiteur de transporteur d'acide urique et sa forme cristalline
EP3725786A4 (fr)	2021-04-28	Forme cristalline et forme de sel d'un inhibiteur de tgf-bri et procédé de préparation correspondant
PT3515454T (pt)	2021-01-18	Forma polimórfica cristalina de 3-hidroxi-4,5-bis-benziloxi-6-benziloximetil-2-fenil-2-oxo-2lambda5-[1,2]oxafosfinano
EP3789389A4 (fr)	2022-01-26	Forme cristalline de dérivé de thiophène
MA40585A (fr)	2021-04-14	Sel de dérivé de céphalosporine, forme solide cristalline de celui-ci et son procédé de production
EP3395819A4 (fr)	2019-05-29	Forme cristalline de dérivé aminopyrane substitué
EP3348546A4 (fr)	2019-03-27	Forme cristalline d'un inhibiteur de récepteur d'androgène et son procédé de préparation